Platinum Investment Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Platinum Investment Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-8,636	Closed	-$3.1M	–	144
2023 Q3	$3.1M	Hold	8,636	–	–	0.12%	64
2023 Q2	$3.27M	Sell	8,636 -9,706	-53%	-$3.95M	0.11%	70
2023 Q1	$8.79M	Sell	18,342 -1,869	-9%	-$875K	0.31%	44
2022 Q4	$8.5M	Hold	20,211	–	–	0.32%	42
2022 Q3	$8.43M	Buy	20,211 +5,507	+37%	+$2.75M	0.35%	42
2022 Q2	$7.28M	Hold	14,704	–	–	0.28%	47
2022 Q1	$8.28M	Buy	14,704 +8,219	+127%	+$4.95M	0.25%	48
2021 Q4	$4.9M	Hold	6,485	–	–	0.14%	62
2021 Q3	$4.84M	Sell	6,485 -5,074	-44%	-$3.8M	0.14%	65
2021 Q2	$7.45M	Buy	11,559 +3,978	+52%	+$2.42M	0.17%	53
2021 Q1	$4.33M	Buy	7,581 +3,557	+88%	+$2.11M	0.1%	62
2020 Q4	$2.35M	Buy	4,024 +1,662	+70%	+$947K	0.05%	87
2020 Q3	$1.22M	Sell	2,362 -706	-23%	-$358K	0.03%	102
2020 Q2	$1.39M	Sell	3,068 -1,107	-27%	-$489K	0.03%	97
2020 Q1	$1.46M	Buy	+4,175	New	+$1.54M	0.04%	83

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Platinum Investment Management's BIO Position: Q4 2023 in Review

Platinum Investment Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 8,636 shares — an estimated $3.1M sold.

Platinum Investment Management first reported a position in BIO in Q1 2020 and held it in 15 quarters. The position peaked at $8.79M in Q1 2023. 483 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

Platinum Investment Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
Platinum Investment Management sold 8,636 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $3.1M.
Platinum Investment Management first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 15 quarters.
Platinum Investment Management's Bio-Rad Laboratories Class A position peaked at $8.79M in Q1 2023.
483 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on Platinum Investment Management's 13F filing for Q4 2023, filed 13 Feb 2024.